EVE Health Promotes COO to CEO as Women’s and Men’s Health Products Near Launch
EVE Health Group has appointed Ben Rohr as Chief Executive Officer effective 27 April 2026, promoting him from Chief Operating Officer. The internal promotion signals the board’s focus on accelerating commercialisation of the company’s Dyspro® and Libbo® product portfolio, with Rohr bringing operational leadership and capital management experience to the executive role.
As part of the transition, Damian Wood steps down from the CEO position but remains with the company as Head of Regulatory and Medical Affairs. This revised structure separates commercial execution from regulatory and clinical expertise, aligning leadership with EVE’s current strategic priorities as it progresses toward product commercialisation.
What does a CEO transition mean for ASX small caps?
In life sciences companies, CEO appointments often reflect strategic inflection points rather than operational instability. The separation of commercial leadership from regulatory and clinical expertise is common as companies transition from development stage toward commercialisation.
For early-stage biotech and pharmaceutical companies, regulatory progression requires dedicated clinical and compliance leadership. As products advance through regulatory pathways and approach commercial launch, boards typically elevate operational and commercial expertise to the CEO level while retaining specialist regulatory talent in focused roles.
EVE’s leadership restructure reflects this pattern. The company’s lead assets, Dyspro® and Libbo®, are positioned for regulatory progression and commercial rollout, requiring execution-focused leadership whilst maintaining regulatory continuity.
When big ASX news breaks, our subscribers know first
Rohr’s track record positions EVE for execution phase
Rohr has led key operational initiatives during his tenure as Chief Operating Officer, including the integration of the Nextract acquisition and advancement of pharmaceutical and commercial development programmes. His involvement in positioning Dyspro® and Libbo® for regulatory progression and commercial rollout provides continuity as the company enters its execution phase.
The appointment comes with a base salary of $220,000 per annum plus superannuation and a 3-month notice period. Rohr currently holds 2,900,000 unlisted options exercisable at $0.06 per option under the Company’s Employee Incentive Plan, issued in December 2025 with a 3-year term.
Chairman Rod Hannington
“Ben has demonstrated strong leadership and a clear ability to execute on the Company’s strategy. His deep understanding of the business, combined with his commercial focus, positions him well to lead EVE through its next phase of growth.”
The options structure creates meaningful upside alignment with shareholders, with the low exercise price incentivising value creation from current levels.
Leadership structure now separates commercial and regulatory functions
The revised executive structure allocates distinct responsibilities between commercial and regulatory functions. Rohr leads commercial execution, operational leadership and capital management, whilst Wood maintains responsibility for regulatory strategy, clinical development and medical affairs across the product pipeline.
Wood was instrumental in advancing EVE’s regulatory and clinical programmes during his tenure as CEO. His retention in a focused regulatory role maintains continuity in compliance expertise whilst allowing Rohr to concentrate on commercialisation objectives.
The new structure positions the company to execute across both regulatory and commercial workstreams:
- CEO (Ben Rohr): Commercial execution, operational leadership, capital management
- Head of Regulatory and Medical Affairs (Damian Wood): Regulatory strategy, clinical development, medical affairs across product pipeline
This alignment reduces execution risk during the commercialisation phase by dedicating specialist expertise to regulatory progression whilst elevating commercial leadership.
The next major ASX story will hit our subscribers first
Near-term catalysts for EVE’s product portfolio
EVE’s lead assets leverage proprietary formulation and delivery technologies for enhanced bioavailability. Dyspro® is a cannabinoid-based pastille targeting dysmenorrhoea and endometriosis, designed for fast-acting symptom relief. Libbo® is an oral dissolving film for erectile dysfunction with rapid onset characteristics.
Both products integrate with digital platforms that provide patient engagement and prescribing pathways. ReclaimMyCycle.com targets women’s health education and treatment access, whilst StiffIssue.com addresses men’s health conditions. These platforms connect telehealth and pharmacy fulfilment networks to enable scalable access within regulated healthcare frameworks.
Key product characteristics include:
- Dyspro®: Fast-acting cannabinoid pastille targeting women’s health (dysmenorrhoea, endometriosis)
- Libbo®: Oral dissolving film for erectile dysfunction with rapid onset design
- Digital platforms: Integrate telehealth and pharmacy fulfilment networks for patient engagement and treatment access
The CEO appointment is timed as both products approach regulatory and commercial milestones. The leadership transition positions EVE to capitalise on near-term opportunities as products progress through regulatory pathways toward potential commercial launch.
Key appointment terms at a glance
| Term | Detail |
|---|---|
| Role | Chief Executive Officer |
| Commencement Date | 27 April 2026 |
| Base Salary | $220,000 p.a. + super |
| Notice Period | 3 months |
| LTI Holdings | 2,900,000 options @ $0.06 |
The appointment reflects EVE’s transition from development-focused operations toward commercialisation execution, with leadership now structured to support regulatory progression and market entry across its product portfolio.
Get Healthcare News Before the Market Reacts
Join 20,000+ investors receiving FREE breaking ASX healthcare announcements delivered to your inbox within minutes of release, complete with expert analysis. Click the “Free Alerts” button at Big News Blast to stay ahead on leadership changes, regulatory milestones and commercial developments across the sector.